Cheli Melzer Cohen

1.9k total citations · 1 hit paper
30 papers, 519 citations indexed

About

Cheli Melzer Cohen is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Cheli Melzer Cohen has authored 30 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Cheli Melzer Cohen's work include Diabetes Treatment and Management (21 papers), Diabetes Management and Research (13 papers) and Metabolism, Diabetes, and Cancer (10 papers). Cheli Melzer Cohen is often cited by papers focused on Diabetes Treatment and Management (21 papers), Diabetes Management and Research (13 papers) and Metabolism, Diabetes, and Cancer (10 papers). Cheli Melzer Cohen collaborates with scholars based in Israel, United States and Netherlands. Cheli Melzer Cohen's co-authors include Gabriel Chodick, Avraham Karasik, Varda Shalev, Mikhail Kosiborod, Hiddo J.L. Heerspink, Marcus Thuresson, Eric Wittbrodt, Shun Kohsaka, Peter Fenici and Rena Pollack and has published in prestigious journals such as Diabetes Care, Diabetes and Diabetologia.

In The Last Decade

Cheli Melzer Cohen

30 papers receiving 514 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

2019 223 citations Hiddo J.L. Heerspink, Avraham Karasik et al. profile →

Peers

Countries citing papers authored by Cheli Melzer Cohen

Since Specialization

Citations

This map shows the geographic impact of Cheli Melzer Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheli Melzer Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheli Melzer Cohen more than expected).

Fields of papers citing papers by Cheli Melzer Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheli Melzer Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheli Melzer Cohen. The network helps show where Cheli Melzer Cohen may publish in the future.

Co-authorship network of co-authors of Cheli Melzer Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Cheli Melzer Cohen. A scholar is included among the top collaborators of Cheli Melzer Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheli Melzer Cohen. Cheli Melzer Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes 2025 ·Diabetes Research and Clinical Practice ·Cheli Melzer Cohen, Ofri Mosenzon, (unknown), Avraham Karasik, Meir Schechter	1
2	Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria 2024 ·Diabetes Obesity and Metabolism ·Afif Nakhleh, Muhammad Abdul‐Ghani, Sivan Gazit, (unknown), (unknown), (unknown), (unknown), Khaled Khazim, Naim Shehadeh, Cheli Melzer Cohen	4
3	Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease 2023 ·Clinical Journal of the American Society of Nephrology ·Cheli Melzer Cohen, Meir Schechter, Aliza Rozenberg, Ilan Yanuv, (unknown), (unknown), Doron Rosenzweig, Gabriel Chodick, Avraham Karasik, Ofri Mosenzon	11
4	Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer: Case-Control Study 2023 ·JMIR Public Health and Surveillance ·Irit Ben‐Aharon, Ran S. Rotem, Cheli Melzer Cohen, Gilad Twig, Andrea Cercek, Elizabeth Half, Tal Goshen‐Lago, (unknown), David P. Kelsen	4
5	Real-World Use of Alirocumab: Experience from a Large Healthcare Provider 2023 ·Journal of Clinical Medicine ·Avishay Elis, Cheli Melzer Cohen, Gabriel Chodick	1
6	Obesity in late adolescence and incident type 1 diabetes in young adulthood 2022 ·Diabetologia ·Inbar Zucker, (unknown), Aya Bardugo, Avishai M. Tsur, Miri Lutski, (unknown), Tali Cukierman‐Yaffe, (unknown), Estela Derazne, Dorit Tzur, Cheli Melzer Cohen, Orit Pinhas‐Hamiel, Gabriel Chodick, Itamar Raz, Arnon Afek, Hertzel C. Gerstein, Amir Tirosh, Gilad Twig	34
7	Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel 2022 ·Diabetes Care ·(unknown), Yingying Sang, Elizabeth Selvin, Alex R. Chang, G. Caleb Alexander, Cheli Melzer Cohen, Josef Coresh, Varda Shalev, Gabriel Chodick, Avraham Karasik, Juan Jesús Carrero, Edouard L. Fu, Yang Xu, Morgan E. Grams, Jung‐Im Shin	13
8	Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults 2022 ·Cardiovascular Diabetology ·Meir Schechter, Cheli Melzer Cohen, Ilan Yanuv, Aliza Rozenberg, Gabriel Chodick, Johan Bodegård, Lawrence A. Leiter, Subodh Verma, Hiddo J.L. Heerspink, Avraham Karasik, Ofri Mosenzon	16
9	All-cause mortality prediction in T2D patients with iTirps 2022 ·Artificial Intelligence in Medicine ·(unknown), Cheli Melzer Cohen, (unknown), Varda Shalev, (unknown), Robert Moskovitch	4
10	Temporal patterns selection for All-Cause Mortality prediction in T2D with ANNs 2022 ·Journal of Biomedical Informatics ·(unknown), Cheli Melzer Cohen, (unknown), (unknown), Robert Moskovitch	11
11	Short-Term Excess Healthcare Costs Associated with Cardiovascular Events Among Adults with Type 2 Diabetes in Israel: A Retrospective Cohort Study 2021 ·PharmacoEconomics - Open ·Cheli Melzer Cohen, (unknown), Gabriel Chodick, (unknown), (unknown), Avraham Karasik	1
12	Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence 2021 ·Cardiovascular Diabetology ·Meir Schechter, Cheli Melzer Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod, Ofri Mosenzon	17
13	Elevated Costs and Healthcare Resource Utilization in Patients With Type 2 Diabetes and Established Cardiovascular Disease in Israel 2020 ·Value in Health Regional Issues ·Cheli Melzer Cohen, (unknown), Gabriel Chodick, (unknown), (unknown), Avraham Karasik	4
14	A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes 2019 ·Diabetes Therapy ·Cheli Melzer Cohen, Gabriel Chodick, Lise Lotte N. Husemoen, Nicolai A. Rhee, Varda Shalev, Avraham Karasik	10
15	1508-P: Trends in Treatment Initiation and Management of Type 2 Diabetes Mellitus: Analysis of 20 Years of Real-World Data 2019 ·Diabetes ·Cheli Melzer Cohen, Varda Shalev, Gabriel Chodick	2
16	Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting 2019 ·Diabetes Therapy ·Cheli Melzer Cohen, Gabriel Chodick, (unknown), Naim Shehadeh, Avraham Karasik	28
17	Anxiolytic treatment but not anxiety itself causes hyponatremia among anxious patients 2019 ·Medicine ·Mayan Gilboa, Gideon Koren, (unknown), Cheli Melzer Cohen, Varda Shalev, Ehud Grossman	2
18	Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction 2018 ·Current Medical Research and Opinion ·Cheli Melzer Cohen, Avraham Karasik, (unknown), Joseph Azuri, Varda Shalev, Gabriel Chodick	2
19	Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study 2017 ·Diabetes Therapy ·Cheli Melzer Cohen, Brian Larsen Thorsted, Michael Lyng Wolden, Gabriel Chodick, Avraham Karasik	7
20	Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study 2016 ·Journal of Diabetes and its Complications ·Inbal Goldshtein, Avraham Karasik, Cheli Melzer Cohen, Samuel S. Engel, Shengsheng Yu, Ofer Sharon, Kimberly G. Brodovicz, Noga Gadir, Harvey L. Katzeff, Larry Radican, Gabriel Chodick, Varda Shalev, Kaan Tunceli	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact